A citation-based method for searching scientific literature

Payal D Shah, Susan M Domchek. Breast J 2020
Times Cited: 3







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
100

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
644
100

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Mark E Robson, Angela R Bradbury, Banu Arun, Susan M Domchek, James M Ford, Heather L Hampel, Stephen M Lipkin, Sapna Syngal, Dana S Wollins, Noralane M Lindor. J Clin Oncol 2015
309
66

National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko. J Clin Oncol 2017
141
66

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
259
66

The Angelina effect: immediate reach, grasp, and impact of going public.
Dina L G Borzekowski, Yue Guan, Katherine C Smith, Lori H Erby, Debra L Roter. Genet Med 2014
95
33

Educational needs and preferred methods of learning among Florida practitioners who order genetic testing for hereditary breast and ovarian cancer.
Deborah Cragun, Andrea Doty Besharat, Courtney Lewis, Susan T Vadaparampil, Tuya Pal. J Cancer Educ 2013
12
33

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
33


Gynecologists' training, knowledge, and experiences in genetics: a survey.
L Wilkins-Haug, L D Hill, M L Power, G B Holzman, J Schulkin. Obstet Gynecol 2000
47
33


The Impact of Direct-to-Consumer Genetic Testing on Patient and Provider.
Mary Beth Palko Dinulos, Stephanie E Vallee. Clin Lab Med 2020
4
33

Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Cecelia A Bellcross, Katherine Kolor, Katrina A B Goddard, Ralph J Coates, Michele Reyes, Muin J Khoury. Am J Prev Med 2011
113
33



Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study.
Bhuma Krishnamachari, Mahin Rehman, Jason E Cohn, Vivian Chan, Neil Modi, Ofri Leitner, Kelly Tangney, April O'Connor, William Blazey, Sharon Koehler,[...]. J Cancer Educ 2018
4
33

Effectiveness of oncogenetics training on general practitioners' consultation skills: a randomized controlled trial.
Elisa J F Houwink, Arno M M Muijtjens, Sarah R van Teeffelen, Lidewij Henneman, Jan Joost Rethans, Liesbeth E J van der Jagt, Scheltus J van Luijk, Geert Jan Dinant, Cees van der Vleuten, Martina C Cornel. Genet Med 2014
22
33

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
121
33

Educating health-care professionals about genetics and genomics.
Alan E Guttmacher, Mary E Porteous, Joseph D McInerney. Nat Rev Genet 2007
197
33

Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.
Jada G Hamilton, Ekland Abdiwahab, Heather M Edwards, Min-Lin Fang, Andrew Jdayani, Erica S Breslau. J Gen Intern Med 2017
50
33

Lynch syndrome: barriers to and facilitators of screening and disease management.
Kathy E Watkins, Christine Y Way, Jacqueline J Fiander, Robert J Meadus, Mary Jane Esplen, Jane S Green, Valerie C Ludlow, Holly A Etchegary, Patrick S Parfrey. Hered Cancer Clin Pract 2011
24
33


Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
Kerstin Rhiem, Hans-Joachim Bücker-Nott, Martin Hellmich, Holger Fischer, Beyhan Ataseven, Christine Dittmer-Grabowski, Kunibert Latos, Volker Pelzer, Manuela Seifert, Andrea Schmidt,[...]. Breast J 2019
11
33

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
33

BRCA1/2 mutations and triple negative breast cancers.
Beth N Peshkin, Michelle L Alabek, Claudine Isaacs. Breast Dis 2010
77
33

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew, Jonathan Ledermann, Geoff Hall, Daniel Rea, Ros Glasspool, Martin Highley, Gordon Jayson, Julieann Sludden, James Murray, David Jamieson,[...]. Br J Cancer 2016
79
33

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Ella R Thompson, Simone M Rowley, Na Li, Simone McInerny, Lisa Devereux, Michelle W Wong-Brown, Alison H Trainer, Gillian Mitchell, Rodney J Scott, Paul A James,[...]. J Clin Oncol 2016
113
33

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman, Bryony Eccles, Sue Gerty, Lorraine T Durcan, Louise Jones,[...]. Lancet Oncol 2018
137
33

Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Soley Bayraktar, Michelle Jackson, Angelica M Gutierrez-Barrera, Diane Liu, Funda Meric-Bernstam, Amanda Brandt, Ashley Woodson, Jennifer Litton, Karen H Lu, Vicente Valero,[...]. Breast J 2015
12
33


Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
Mary B Daly, Robert Pilarski, Jennifer E Axilbund, Michael Berry, Saundra S Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E Garber, Seema Khan,[...]. J Natl Compr Canc Netw 2016
112
33


Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis.
Eun-Ha Lee, Sue K Park, Boyoung Park, Sung-Won Kim, Min Hyuk Lee, Sei Hyun Ahn, Byung Ho Son, Keun-Young Yoo, Daehee Kang. Breast Cancer Res Treat 2010
57
33

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Sarah L Blair, Harold J Burstein, Chau Dang, Anthony D Elias,[...]. J Natl Compr Canc Netw 2020
186
33

Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Pawel Domagala, Cezary Cybulski, Oleg Oszurek, Marek Szwiec, Karol Gugala, Malgorzata Stawicka,[...]. J Clin Oncol 2013
73
33

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
33

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
33

Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.
Alexandra J van den Broek, Marjanka K Schmidt, Laura J van 't Veer, Rob A E M Tollenaar, Flora E van Leeuwen. PLoS One 2015
52
33

Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience.
Seth K Rummel, Leann A Lovejoy, Clesson E Turner, Craig D Shriver, Rachel E Ellsworth. Cancers (Basel) 2020
5
33

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
33

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli,[...]. Ann Oncol 2018
106
33

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Heidi D Nelson, Miranda Pappas, Bernadette Zakher, Jennifer Priest Mitchell, Leila Okinaka-Hu, Rongwei Fu. Ann Intern Med 2014
157
33

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
328
33

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
Lynn C Hartmann, Noralane M Lindor. N Engl J Med 2016
150
33

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Susan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer,[...]. Gynecol Oncol 2016
151
33

Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Lovise Mæhle, Dag Erik Undlien, Jan Norum, Ellen Schlichting. BMC Cancer 2017
31
33

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Shari Gelber, Lidia Schapira, Steven Come, Virginia F Borges, Bryce Larsen, Judy E Garber, Ann H Partridge. JAMA Oncol 2016
74
33


Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Felipe Batalini, Ellie G Peacock, Lindsey Stobie, Alison Robertson, Judy Garber, Jeffrey N Weitzel, Nadine M Tung. Breast Cancer Res 2019
18
33

Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Omar Alejandro Zayas-Villanueva, Luis Daniel Campos-Acevedo, José de Jesús Lugo-Trampe, David Hernández-Barajas, Juan Francisco González-Guerrero, María Fernanda Noriega-Iriondo, Ilse Alejandra Ramírez-Sánchez, Laura Elia Martínez-de-Villarreal. BMC Cancer 2019
4
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.